SuperworthGeneDx price to sales ratio WGS
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- 3.7×
- 5-year median
- 3.5×
- Against its 5-year history
- 52nd
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 0.2× to 12.0×
- Peer median
- 1.3×
GeneDx's price to sales ratio is 3.7× as of Oct 23, 2026.
That is above its 5-year median of 3.5×, close to the middle of its last 5 years.
Over that time it ranged from 0.2× in Nov 2023 to 12.0× in Nov 2025.
The median for 10 hospital and care facility stocks of a similar size is 1.3×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.7× | 2.7× | 9.7× |
| 2025 | 9.6× | 5.1× | 12.0× |
| 2024 | 8.0× | 0.3× | 8.1× |
| 2023 | 0.3× | 0.2× | 1.2× |
| 2022 | 0.4× | 0.4× | 4.5× |
Against its peers
Companies in Medical - Care Facilities nearest GeneDx's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| WGSGeneDx | 3.7× |
| ARDTArdent Health | 0.3× |
| HCSGHealthcare Services | 0.9× |
| PNTGPennant | 1.3× |
| USPHU S Physical Therapy | 1.6× |
| PGNYProgyny | 1.7× |
| ADUSAddus HomeCare | 1.5× |
| MDPediatrix Medical | 1.2× |
| OMDAOmada Health | 3.7× |
| PRVAPrivia Health | 1.2× |
| AVAHAveanna Healthcare | 1.1× |
| Peer median | 1.3× |
Where GeneDx ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on GeneDx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.